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INTRODUCTION
Systematic reviews of randomised controlled trials (RCT) have shown that probiotic supplementation improves the outcomes of preterm (non-surgical) infants [1] [2] [3] [4] [5] [6] . The role of probiotics in neonates with gastrointestinal surgical conditions has not been explored adequately. Since these infants are exposed to multiple courses of antibiotics, receive enteral feeds slowly, and have less opportunities for skin to skin contact with their mothers, they are susceptible to develop gut dysbiosis through similar mechanisms that are operational in preterm infants [7] [8] [9] [10] [11] [12] . Considering their beneficial properties, probiotics may improve the outcomes of neonates with surgical conditions of the gut.
However, since the gut integrity is disrupted by the disease process or the surgical procedure, neonates with gastrointestinal anomalies are theoretically at increased risk of developing sepsis due to the administered probiotic organism. There is limited data on the use of probiotics in neonates with gastrointestinal surgical conditions [17] [18] [19] . In our neonatal
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intensive care unit (NICU), it is routine practice to give probiotic Bifidobacterium breve (B. breve)M-16V supplementation to all preterm infants born <33weeks' gestation (both surgical and nonsurgical), which is continued till the postmenstrual age of 37weeks. Given the potential risks associated, we conducted this audit to assess the safety of probiotics in neonates with GI surgical conditions.
Aim of the study
To assess the safety of B. breve M-16V supplementation in preterm infants with GI surgical conditions in our unit.
MATERIALS AND METHODS
Type of study: A retrospective audit using prospectively collected data Ethics Approval: The study was approved by the hospital's quality improvement committee as having met the 'Australian National Health and Medical Research Council requirements for quality assurance and audit projects'.
Participants: All preterm infants born <33 weeks gestation, who had gastrointestinal conditions requiring surgery and received probiotic supplementation either before and/or after surgery were included. This study was conducted at our Level 3 surgical neonatal intensive care unit (January 2013 to October 2016). Neonatal databases were screened to identify eligible infants. The data were collected from the medical records and discharge summaries of infants using a structured form. The idea behind our audit was to collect all the cases where in either gut mucosal integrity was interfered with or gut was manually handled during surgery. Probiotic associated sepsis was defined as the identification of Bifidobacteria in the blood or other body fluids in supplemented infants using DNA technology and routine culture techniques.
Probiotic (B. breve M-16V) protocol: The supplementation was started as single dose of 1.5 billion colony forming units (CFU) per day while on minimal enteral feeds and increased to two doses (3 billion CFU) per day when on full enteral feeds. The supplementation was withheld if the infant was not on feeds for any reason (e.g. sepsis, surgery, severe feed intolerance, critical illness).
Statistical Analysis: Statistical analysis was performed using Stata 13.0 (STATA Corp., TX, USA). The median, interquartile range (IQR), and range were calculated for data with skewed distribution. Percentages were calculated for categorical data. Given the small sample size and heterogeneity, analysis to compare the outcomes of infants who received probiotics in the pre-surgical period versus those who did not receive the supplements in the pre-surgical period was not done.
RESULTS
Thirty-three preterm infants who underwent 43 gastrointestinal surgeries and received probiotic were eligible for inclusion. Twenty-three (69.6%) infants underwent one episode of surgery whereas the remaining 10 (30.4%) had 2 episodes of surgery during their stay. Out of the 33 infants, 14(42.4%) were female. Indications for surgery included NEC (n=8), malrotation (n=5), non-NEC intestinal perforations (n=4), duodenal atresia (n=3), intestinal obstruction (n=3), tracheo esophageal fistula (n=3), pyloric stenosis (n=2), gastroschisis (n=2), esophageal perforation (n=1), hepatic cyst (n=1) and congenital diaphragmatic hernia (n=1). The median gestational age at the time of initial surgery was 30.8 weeks. The detailed demographic, anthropometry and feeding patterns have been described in table 1.
Of the 33 infants, 12 (36.3%) received probiotics before the surgery, 24 (72.7%) received after the surgery and 10 (30.3%) received both before and after surgery. The median post-operative day at the time of commencement of probiotics was day 10. The details of commencement of probiotic supplementation, relation to timing of surgical procedure, total number of dosages and total number of days of supplementation have been described in table 2.
All except one infant survived and were discharged home or transferred to regional hospitals. The infant who died had midgut volvulus with extensive necrosis. None of the supplemented infants developed sepsis due to the administered probiotic strain. One infant grew B. breve in the pleural fluid even before probiotics were commenced, due to cross colonization. Summary of all cases is described in table 3. Seven infants had blood stream infection due to Coagulase negative staphylococci (CONS), one had E Coli sepsis, one had CONS and Enterococcal sepsis, one had sepsis due to CONS and E Coli and one had sepsis due to CONS, E. coli and Enterobacter fecalis in the immediate peri operative period while they had not yet been commenced on probiotics supplementation. All of them responded to standard antibiotic regimens. 
DISCUSSION
This retrospective study of 33 preterm infants (<33 weeks' gestation) with GI surgical conditions describes our experience with the use of probiotic B. breve M-16V. Majority of the cases involved interference with gut mucosal integrity during surgery or by disease process e.g., NEC, non-NEC intestinal perforations, duodenal atresia, intestinal obstruction, tracheo esophageal fistula and esophageal perforation. Other cases involved manual handling of the gut during surgery which may result in altered physiological function and permeability e.g., malrotation, pyloric stenosis, gastroschisis, hepatic cyst and congenital diaphragmatic hernia. It was reassuring to know that none of our study infants developed peritonitis or blood stream infection due to the probiotic organism. It is also reassuring to know that none of the infants developed health care associated blood stream infections after commencement of the probiotic supplementation in post-operative period. All blood stream infections which occurred in the immediate perioperative period were when the probiotic supplementation had not yet been commenced. Analysis of difference between the groups was not attempted due to heterogeneity of cases and small sample size.
Standard laboratory techniques may not detect the probiotic organisms and hence may lead to false reassurance regarding the probiotic safety [20] . However, our microbiology laboratory is well equipped to detect B. breve in routinely collected specimens such as blood and other body fluids. This was demonstrated by the detection of B. breve species from the pleural fluid that was sent for routine microscopy and cultures on one of the study infants.
To our knowledge our study has the highest sample size so far on probiotic supplementation in preterm infants with GI surgical conditions. Our results add important data to the field of probiotic supplementation in this cohort. There are few studies reporting on tolerance of probiotic supplements in gastrointestinal surgical conditions in infants born >34 weeks. Powell et al. in their pilot randomized placebo-controlled trial found that administration of B. infantis American type, in 10 infants with gastroschisis born at >34 weeks gestation, was tolerated well and lead to good colonization of gut [18] . Murakami et al studied four term infants who required gut surgery and tolerated the supplementation of Bifidobacterium animalis subsp. Lactis [19] .
There are few case reports of probiotic sepsis in neonates undergoing gut surgery. Brecht et al. reported a case of Lactobacillus sepsis 52 days following a second laparotomy for spontaneous intestinal perforation in a preterm infant. The infant had received Infloran (a combination of B. bifidum and Lactobacillus acidophilus) from 7 days after the second laparotomy [13] . longum [16] .
The limitations of our study include the retrospective design without controls, heterogeneous nature of the surgical conditions and the small sample size. Another limitation was the fact that we did not do routine fecal microbiota studies to assess gut dysbiosis. While the results of our study are reassuring, the reports of probiotic sepsis in surgical neonates described above, suggest the need for caution and the need for well conducted RCTs in this high-risk population. Such RCTs should be adequately powered to evaluate clinically relevant outcomes such as mortality, healthcare associated blood stream infections (HABSI), ventilator associated pneumonia, other hospital acquired infections (HAI), duration of antibiotic therapy, gut microbiota, inflammatory markers (e.g., high sensitivity CReactive Protein), feed tolerance, scores of physical growth at the time of discharge and most importantly, sepsis due to the supplemented probiotic organism. Stratification of the study participants based on the underlying surgical condition would also be essential, given the heterogeneous nature of the gastrointestinal surgical conditions in neonates.
CONCLUSION
Probiotic sepsis did not occur following B. breve M-16V supplementation in our small cohort of preterm infants with gastrointestinal surgical conditions. Adequately powered randomised controlled trials are needed to confirm the safety and efficacy of B. breve M-16V in this cohort. Note: Following this audit, we are in the process of conducting a RCT in near future.
